Clinical Trial

Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 17, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective, multicentre, randomized, open-label, blinded-endpoint clinical trial to evaluate the efficacy and safety of Yangxinshi tablets in the treatment of patients with chronic coronary syndrome (CCS).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-05.
Status change: Not Yet Recruiting → Recruiting 2024-04-16
Trial Details
NCT Number NCT06171061
Lead Sponsor Shandong First Medical University
Conditions Chronic Coronary Syndrome
Enrollment 1,200 participants
Start Date 2023-12-18
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-04-17